Targeting RNA G-Quadruplex in SARS-CoV-2: A Promising Therapeutic Target for COVID-19?

Angew Chem Int Ed Engl. 2021 Jan 4;60(1):432-438. doi: 10.1002/anie.202011419. Epub 2020 Oct 27.

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 has become a global threat. Understanding the underlying mechanisms and developing innovative treatments are extremely urgent. G-quadruplexes (G4s) are important noncanonical nucleic acid structures with distinct biofunctions. Four putative G4-forming sequences (PQSs) in the SARS-CoV-2 genome were studied. One of them (RG-1), which locates in the coding sequence region of SARS-CoV-2 nucleocapsid phosphoprotein (N), has been verified to form a stable RNA G4 structure in live cells. G4-specific compounds, such as PDP (pyridostatin derivative), can stabilize RG-1 G4 and significantly reduce the protein levels of SARS-CoV-2 N by inhibiting its translation both in vitro and in vivo. This result is the first evidence that PQSs in SARS-CoV-2 can form G4 structures in live cells, and that their biofunctions can be regulated by a G4-specific stabilizer. This finding will provide new insights into developing novel antiviral drugs against COVID-19.

Keywords: G-quadruplex; RNA; drug discovery; inhibitors; viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • COVID-19 Drug Treatment*
  • Drug Evaluation, Preclinical
  • G-Quadruplexes / drug effects*
  • Gene Expression Regulation, Viral / drug effects
  • Genome, Viral
  • Humans
  • Nucleocapsid Proteins / chemistry
  • Nucleocapsid Proteins / drug effects
  • Protein Folding
  • RNA, Viral / drug effects*
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / genetics
  • Small Molecule Libraries
  • Temperature

Substances

  • Antiviral Agents
  • Nucleocapsid Proteins
  • RNA, Viral
  • Small Molecule Libraries